Janney Montgomery Scott analyst Robert Stevenson upgrades NexPoint Residential (NYSE:NXRT) from Neutral to Buy.
Ascendis Pharma Announces The FDA Accepts For Review Resubmitted NDA For TransCon PTH In Adult Patients With Hypoparathyroidism
Ascendis Pharma A/S (NASDAQ:ASND) today announced that the U.S. Food & Drug Administration (FDA) has accepted for review the Company's resubmitted New Drug Application (NDA) for TransCon PTH (palopegteriparatide) for
